Skip to main content

Table 5 AEs occurring in ≥ 2% of patients

From: Evaluation of inhaler technique and achievement and maintenance of mastery of budesonide/formoterol Spiromax® compared with budesonide/formoterol Turbuhaler® in adult patients with asthma: the Easy Low Instruction Over Time (ELIOT) study

 

BF Spiromax

(N = 197)

BF Turbuhaler

(N = 197)

Patients with at least 1 AE, n (%)

113 (57.4)

119 (60.4)

 Infections and infestations

  Lower respiratory tract infection

17 (8.6)

31 (15.7)

  Urinary tract infection

5 (2.5)

2 (1.0)

 Nervous system disorders

  Headache

5 (2.5)

2 (1.0)

 Respiratory, thoracic, and mediastinal disorders

  Asthma (worsening of asthma or asthma attack)

8 (4.1)

9 (4.6)

  Cough

11 (5.6)

12 (6.1)

  Dyspnea

5 (2.5)

5 (2.5)

  Wheezing

4 (2.0)

3 (1.5)

Number of patients with at least 1 serious AE, n (%)

4 (2.0)

8 (4.1)

  1. AE adverse event, BF budesonide formoterol